The role of MYEOV gene: a review and future directions by Yidan Xi, Xuefei Liu, Yanan Ge, Mingzhe Jiang, Dong Zhao, Ershu Zhao, Fei Cai, Xinlong Wang, Jiatong Li, Tingting Li, Zhendong Zheng

Get full text

First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a rand... by Yuankai Shi, Yi Ba, Junye Wang, Jianping Xiong, Kangsheng Gu, Yigui Chen, Zhendong Zheng, Zishu Wang, Weijian Guo, Ying Cheng, Xianli Yin, Yunpeng Liu, Yuxian Bai, Enxiao Li, Qi Li, Liangjun Zhu, Wei Li, Da Jiang, Jingdong He, Jiansi Chen, Jianguo Sun, Sheng Hou

Get full text

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial by Chuanhua Zhao, Yanqiao Zhang, Gang Wang, Jinfang Zheng, Weiqing Chen, Zheng Lu, Li Zhuang, Shanzhi Gu, Lei Han, Zhendong Zheng, Zujiang Yu, Yongsheng Yang, Hongmei Sun, Xiaoyong Wei, Ying Cheng, Hailan Lin, Bo Zhu, Guicheng Wu, Kaijian Lei, Wei Wang, Yuwen Wang, Kehe Chen, Ximing Xu, Cuiping Zheng, Yanzhi Bi, Sijuan Ding, Jingdong Zhang, Wei Li, Hailong Liu, Jun Wang, Xianling Liu, Yangfeng Du, Lianming Cai, Jingran Wang, Zhanxiong Luo, Baocai Xing, Jie Shen, Lin Yang, Jianbing Wu, Ou Jiang, Zhigang Peng, Xiuli Liu, Bangwei Cao, Liangfang Shen, Aibing Xu, Aimin Li, Shaojun Chen, Ting Fu, Jian Chen, Chuan Jin, Lei Zhang, Jun Lv, Chengwu Zhang, Xiaoman Zhang, Yu Wang, Huo Su, Qiang Zhou, Wenlin Gai, Liangzhi Xie, Jianming Xu

Get full text